Tiny trial aims to shed light on PSMA scans in hard-to-treat prostate cancer
NCT ID NCT04925648
First seen May 14, 2026 · Last updated Jun 16, 2026 · Updated 4 times
Summary
This study tested whether taking dasatinib alone or with darolutamide for 14 days can increase PSMA levels on PET scans in men with metastatic prostate cancer. Only 4 men participated, all with low PSMA uptake on their initial scan. The goal was to learn more about how PSMA expression works, not to treat the cancer directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kinghorn Cancer Centre, St. Vincent's Hospital
Sydney, New South Wales, 2010, Australia
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
Conditions
Explore the condition pages connected to this study.